Cyclopentolate ophthalmic solution is primarily used to induce mydriasis (pupil dilation) and cycloplegia (loss of accommodation) for diagnostic eye examinations.

Cyclopentolate is an anticholinergic drug that relaxes the iris sphincter muscle and ciliary muscle. When applied topically in the eye, it produces a rapid and strong cycloplegic and mydriatic effect, reaching maximum action within 15 to 60 minutes. Normal recovery generally occurs within 24 hours. In individuals with darkly pigmented irises, the onset is slower and the duration of action is longer.

To produce mydriasis and cycloplegia for diagnostic purposes, in adults and children over 1 year: 1 drop instilled in the eye(s), followed by a second drop 5 minutes later, if necessary. Drops should be administered 40 to 50 minutes prior to the procedure. To minimize systemic absorption, finger pressure should be applied to the lacrimal sac for 2 to 3 minutes following administration. Alternatively, the eyelids should be kept closed for 2 to 5 minutes following installation. Patients with heavily pigmented irises may require larger doses. Complete recovery from mydriasis and cycloplegia should occur within 24 hours.

Use in children: Infants and young children and children with blond hair or blue eyes may be especially sensitive to the effects of cyclopentolate, increasing the chance of side effects during treatment. Use of cyclopentolate in children has been associated with psychotic reactions and behavioral disturbances.

Cyclopentolate may influence the effects of other concurrently used medicines such as antihistamines, isoniazid, MAO inhibitors, phenothiazines, procainamide, disopyramide, propranolol, quinidine, and tricyclic antidepressants. Anticholinergic drugs like cyclopentolate counteract the effects of cholinesterase inhibitors and cholinergic agonists by preventing miosis and contraction of the ciliary muscle.

Cyclopentolate is contraindicated in patients with angle-closure glaucoma or shallow anterior chamber. It should not be used in patients, especially children, who have previously experienced severe systemic reactions to the drug or who are hypersensitive to any of its components.

Serious effects include acute angle-closure glaucoma and increased intraocular pressure. Mydriasis may be reversed using pilocarpine, physostigmine, or isoflurophate. A transient burning sensation in the eye may occur, especially with 0.5% solution. Systemic absorption or ingestion may cause dry mouth, flushing, tachycardia, and urinary retention. Severe toxicity may lead to rapid breathing, scarlatiniform rash, delirium, psychosis, fever, stupor, coma, respiratory failure, and death.

Cyclopentolate may increase intraocular pressure and can trigger angle-closure glaucoma, especially in elderly patients and those with shallow anterior chambers. Sustained pressure elevation may lead to irreversible vision loss.

If symptoms such as eye pain, blurred vision, rapid heartbeat, or dizziness occur, the drug should be stopped immediately and medical advice sought. Due to light sensitivity caused by pupil dilation, patients may need to wear dark glasses. Blurred vision and sensitivity to light lasting more than 48 hours after stopping the drug should be reported to a physician. Systemic absorption through nasal mucosa may cause adverse effects, particularly in children, who are more vulnerable. If signs like dry mouth, tachycardia, or dizziness appear, the dose should be reduced or discontinued.

Anticholinergics

Store in a cool, dry place away from light. Keep out of reach of children.